Drug intelligence / Profile preview

atezolizumab + denosumab + nivolumab + pembrolizumab + zoledronate

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This is a combination of three immune checkpoint inhibitors (atezolizumab, nivolumab, and pembrolizumab) and two bone-targeting agents (denosumab and zoledronate). The immune checkpoint inhibitors work by blocking the PD-1/PD-L1 pathway to enhance T-cell immune responses against cancer cells. Denosumab is a RANKL inhibitor and zoledronate is a bisphosphonate, both used to prevent skeletal-related events in patients with bone metastases.

Targets

FDPS (Farnesyl pyrophosphate synthase)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + denosumab + nivolumab + pembrolizumab + zoledronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + denosumab + nivolumab + pembrolizumab + zoledronate.

Explore the full profile